-
Latest DPPOS results on CVD, cancer incidence to be reported
The latest clinical outcomes from the largest and longest follow-up to the Diabetes Prevention Program study will be presented during the Virtual 80th Scientific Sessions. The current phase of the Diabetes Prevention Program Outcomes Study (DPPOS) is scheduled to run through 2021 and is examining the long-term effects of metformin on cardiovascular disease and cancer…
-
SEARCH results highlight increasing burden and disparities in youth-onset diabetes
Five experts will review critical lessons from two decades of surveillance and observational research into youth-onset diabetes during a two-hour virtual symposium at the Scientific Sessions. The expert presenters, including symposium chair Dana Dabelea, MD, PhD, are key participants in the SEARCH for Diabetes in Youth Study, a national multi-center study with centers in California,…
-
Session will explore crossover benefits of heart, kidney treatments
“Diabetes-dedicated professionals can be very successful at managing diabetes, but they want to be equally successful in reducing the risks of heart failure hospitalizations, myocardial infarctions, stroke, and cardiovascular death. They want to be equally successful in reducing the progression of kidney disease and reducing the chances of patients ending up on dialysis, or at…
-
Experts will debate recommendations for blood pressure targets, metformin use
Should the blood pressure target for all individuals with type 2 diabetes and hypertension be
-
Make plans to attend virtual Corporate Symposia during the Scientific Sessions
Corporate Symposia are programs that are planned and conducted by the corporate community in conjunction with the Virtual 80th Scientific Sessions to provide attendees with additional educational opportunities. There are currently 10 Corporate Symposia scheduled beginning Friday, June 12.
-
Sympathetic-Associated Macrophages in Energy Homeostasis
Ana Domingos, PhD, previews her presentation “Sympathetic-Associated Macrophages in Energy Homeostasis,” which begins at 5:00 p.m. CT Saturday, June 13.
-
DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?! Background and Main Cardiovascular Outcomes
John JV McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, Professor of Medical Cardiology, University of Glasgow, previews his presentation “DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?! Background and Main Cardiovascular Outcomes,” which begins at 4:00 p.m. CT Saturday, June 13.
-
Efficacy of Personalized Nutrition Based on Gut Microbiome and Clinical Data in Prediabetes
Eran Segal, PhD, previews his presentation “Efficacy of Personalized Nutrition Based on Gut Microbiome and Clinical Data in Prediabetes,” which begins at 11:40 a.m. CT Saturday, June 13.
-
Professional Interest Group Discussion on Nutritional Science and Metabolism—Emerging Methodologies for Personalized Nutrition—Potential Effects on Glycemic and Other Diabetes-Related Outcomes?
Guoxun Chen, PhD, previews his response and discussion from the Professional Interest Group Discussion “Nutritional Science and Metabolism—Emerging Methodologies for Personalized Nutrition—Potential Effects on Glycemic and Other Diabetes-Related Outcomes?” The session begins at 11:30 a.m. CT Saturday, June 13. Dr. Chen’s presentation will begin at 12:10 p.m. CT.
-
The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
John JV McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, Professor of Medical Cardiology, University of Glasgow, previews his presentation “The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial,” which begins at 6 p.m. CT Friday, June 12.